Home » Stocks » GTHX

G1 Therapeutics, Inc. (GTHX)

Stock Price: $19.74 USD -0.86 (-4.17%)
Updated May 10, 2021 4:00 PM EDT - Market closed
Market Cap 842.75M
Revenue (ttm) 57.36M
Net Income (ttm) -94.67M
Shares Out 40.70M
EPS (ttm) -2.45
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 10
Last Price $19.74
Previous Close $20.60
Change ($) -0.86
Change (%) -4.17%
Day's Open 20.41
Day's Range 19.40 - 20.50
Day's Volume 1,490,701
52-Week Range 10.81 - 37.07

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

PRESERVE 4 Will Evaluate the Survival and Myeloprotection Benefits of COSELA in 146 Patients with Non-Small Cell Lung Cancer (NSCLC) Previously Treated with Checkpoint Inhibitors PRESERVE 4 Will Evaluat...

12 hours ago - GlobeNewsWire

RESEARCH TRIANGLE PARK, N.C., May 07, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisabl...

3 days ago - GlobeNewsWire

G1 THERAPEUTICS (GTHX) delivered earnings and revenue surprises of 40.37% and 3711.80%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

4 days ago - Zacks Investment Research

- G1's COSELA™ (trilaciclib), the Only FDA-Approved Proactive Multilineage Myeloprotection Therapy, Approved on February 12, 2021 and Commercially Available as of March 2, 2021 -

5 days ago - GlobeNewsWire

RESEARCH TRIANGLE PARK, N.C., April 28, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate...

1 week ago - GlobeNewsWire

- Pivotal Program Evaluated the Effects of Administering COSELA Prior to Chemotherapy on Clinically Relevant Endpoints Across Multiple Hematopoietic Lineages, Including Hematologic Adverse Events, Labor...

2 weeks ago - GlobeNewsWire

RESEARCH TRIANGLE PARK, N.C., April 07, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that G1's Chief Executive Officer Jack Bailey ...

1 month ago - GlobeNewsWire

RESEARCH TRIANGLE PARK, N.C., April 02, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisa...

1 month ago - GlobeNewsWire

RESEARCH TRIANGLE PARK, N.C., April 01, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will host a virtual COSELA Ki...

1 month ago - GlobeNewsWire

COSELA Added to Both the NCCN Treatment Guidelines for Small Cell Lung Cancer and the NCCN Supportive Care Guidelines for Hematopoietic Growth Factors COSELA Added to Both the NCCN Treatment Guidelines ...

1 month ago - GlobeNewsWire

RESEARCH TRIANGLE PARK, N.C., March 03, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two inves...

2 months ago - GlobeNewsWire

- Launch of Innovative Therapy for People Living with Extensive-Stage Small Cell Lung Cancer is Supported by the G1 to One™ Patient Support Program, the Single Source for COSELA Access Solutions - - Lau...

2 months ago - GlobeNewsWire

Shares of G1 Therapeutics (NASDAQ:GTHX) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 28.72% year over year to ($0.67), which beat the est...

2 months ago - Benzinga

- G1's COSELA™ (trilaciclib) Approved by FDA as First and Only Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression; Commercial Availability Expected in Early March -

2 months ago - GlobeNewsWire

RESEARCH TRIANGLE PARK, N.C., Feb. 17, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate ...

2 months ago - GlobeNewsWire

G1 Therapeutics Inc (NASDAQ: GTHX) shares gain premarket after FDA approves COSELA (trilaciclib) for injection to decrease the incidence of chemotherapy-induced myelosuppression (damage to bone marrow) ...

2 months ago - Benzinga

- COSELA is the only FDA-approved therapy that helps proactively deliver multilineage myeloprotection to patients with extensive-stage small cell lung cancer being treated with chemotherapy -

2 months ago - GlobeNewsWire

RESEARCH TRIANGLE PARK, N.C., Feb. 04, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that G1's Chief Executive Officer Jack Bailey wil...

3 months ago - GlobeNewsWire

NEW YORK--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”) announces its investigation of G1 Therapeutics, Inc. (Nasdaq: GTHX) concerning the Company and its directors' and officers' possible violat...

3 months ago - Business Wire

G1 Therapeutics has a PDUFA date coming up on February 15, 2021 for its first therapy, trilaciclib in SCLC. G1's stock has moved hugely upward over the last few months as investors begin to anticipate t...

3 months ago - Seeking Alpha

RESEARCH TRIANGLE PARK, N.C., Jan. 05, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Jack Bailey will pre...

4 months ago - GlobeNewsWire

- Company also reports inducement grant under Nasdaq Listing Rule 5635(c)(4) -

4 months ago - GlobeNewsWire

Company also presents updated monotherapy data on investigational oral selective estrogen receptor degrader (SERD) rintodestrant for ER+, HER2- breast cancer Company also presents updated monotherapy da...

5 months ago - GlobeNewsWire

GTHX stock is depressed but I don't see any reason. PDUFA of Feb. 15, 2021, is a major catalyst.

5 months ago - Seeking Alpha

RESEARCH TRIANGLE PARK, N.C., Nov. 24, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that incoming Chief Executive Officer Jack Bailey...

5 months ago - GlobeNewsWire

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can ...

Other stocks mentioned: CAR, BH, GSKY, KROS, ORGO, REYN, WTRH
5 months ago - Benzinga

RESEARCH TRIANGLE PARK, N.C., Nov. 18, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that final overall survival (OS) data from its ra...

5 months ago - GlobeNewsWire

RESEARCH TRIANGLE PARK, N.C., Nov. 11, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that Chief Executive Officer Jack Bailey will pre...

5 months ago - GlobeNewsWire

G1 Therapeutics, Inc. (GTHX) CEO Mark Velleca on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

RESEARCH TRIANGLE PARK, N.C., Oct. 28, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it will host a webcast and conference call t...

6 months ago - GlobeNewsWire

RESEARCH TRIANGLE PARK, N.C., Oct. 15, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced that four presentations highlighting the myelopre...

6 months ago - GlobeNewsWire

- Mark Velleca, M.D., Ph.D., G1’s first Chief Executive Officer, to serve as senior advisor and remain member of the G1 Board of Directors

7 months ago - GlobeNewsWire

RESEARCH TRIANGLE PARK, N.C., Sept. 14, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today announced that two presentations highlighting data on ...

7 months ago - GlobeNewsWire

RESEARCH TRIANGLE PARK, N.C., Sept. 02, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today announced that the company will participate in the fol...

8 months ago - GlobeNewsWire

Oncology Stocks Area Trading Materially Lower The Last 2 Months

Other stocks mentioned: BYSI, KPTI, URGN
8 months ago - Seeking Alpha

Of a pool of 26 oncology stocks we track, with 1 exception, all (literally 25 of 26) are trading materially lower from the third week of June 2020.

Other stocks mentioned: BYSI, KPTI, URGN
8 months ago - Seeking Alpha

- PDUFA action date of February 15, 2021 assigned by U.S. Food and Drug Administration - Priority Review for trilaciclib is based on positive data from three randomized clinical trials showing robust m...

8 months ago - GlobeNewsWire

G1 Therapeutics' (GTHX) CEO Mark Velleca on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

- Submitted New Drug Application (NDA) for trilaciclib in small cell lung cancer (SCLC) - Co-promotion agreement with Boehringer Ingelheim for U.S. trilaciclib launch - Partnership for trilaciclib in ...

9 months ago - GlobeNewsWire

RESEARCH TRIANGLE PARK, N.C., Aug. 04, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today announced that Chief Executive Officer Mark Velleca, M....

9 months ago - GlobeNewsWire

RESEARCH TRIANGLE PARK, N.C., July 29, 2020 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today announced that it will host a webcast and conference ca...

9 months ago - GlobeNewsWire

- G1 to receive $20 million upfront payment, sales royalties and potential milestone payments of up to $290 million for commercialization of lerociclib in the U.S., Europe, Japan

9 months ago - GlobeNewsWire

- Partnership leverages Boehringer Ingelheim’s oncology expertise to lead trilaciclib SCLC launch sales engagements - G1 to retain full development and commercialization rights and book revenue for tri...

10 months ago - GlobeNewsWire

G1 Therapeutics Has Multiple Roadmaps To A Multi-Billion Dollar Market Cap

10 months ago - Seeking Alpha

- G1 to receive $6 million upfront payment, sales royalties and up to $40 million in future milestone payments - Genor to lead clinical development, regulatory submissions and commercialization of lero...

10 months ago - GlobeNewsWire

If you have cash to spare, these cancer stocks are set to soar.

Other stocks mentioned: EPZM
10 months ago - The Motley Fool

As investors begin to turn their attention away from Covid-19 and the novel coronavirus, these biotech stocks present excellent opportunities.

Other stocks mentioned: CORT, DVAX, IMGN, KDMN, SUPN, VRTX
10 months ago - InvestorPlace

G1 Therapeutics (GTHX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

10 months ago - Zacks Investment Research

- Non-dilutive capital to support commercialization and additional development of trilaciclib - Non-dilutive capital to support commercialization and additional development of trilaciclib

11 months ago - GlobeNewsWire

Bull market or bear market, one fact remains unwavering: Biotech stocks represent the ultimate risk/reward plays.

Other stocks mentioned: ATRA, DVAX, FIXX, IMGN, KDMN, VKTX
11 months ago - Kiplinger

About GTHX

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor tha... [Read more...]

Industry
Biotechnology
IPO Date
May 17, 2017
CEO
Mark Velleca
Employees
122
Stock Exchange
NASDAQ
Ticker Symbol
GTHX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for GTHX stock is "Buy." The 12-month stock price forecast is 59.00, which is an increase of 198.89% from the latest price.

Price Target
$59.00
(198.89% upside)
Analyst Consensus: Buy